Mirjana Šefik-Bukilica

Immunoserological parameters in SLE: high-avidity anti-dsDNA detected by ELISA are the most closely associated with the disease activity

Sladjana Andrejević, Ivica Jeremić, Mirjana Šefik-Bukilica et al. · Clinical Rheumatology · 2013 · 54 citations

Autoimmune Disease, Systemic Lupus Erythematosus, Lupus +15

Serum DNase I activity in systemic lupus erythematosus: correlation with immunoserological markers, the disease activity and organ involvement

Dušan Škiljević, Ivica Jeremić, Miloš Nikolić et al. · Clinical Chemistry and Laboratory Medicine (CCLM) · 2012 · 52 citations

Is there a difference in systemic lupus erythematosus with and without Raynaud’s phenomenon?

Slavica Pavlov‐Dolijanović, Nemanja Damjanov, Nada Z. Vujasinovic Stupar et al. · Rheumatology International · 2012 · 47 citations

Rheumatology, Autoimmune Disease, Systemic Lupus Erythematosus +9

-174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis

Ivan Jančić, Nevena Arsenović-Ranin, Mirjana Šefik-Bukilica et al. · Rheumatology International · 2012 · 39 citations

Inflammation, Rheumatology, Rheumatoid Disorder +12

Anti–double stranded DNA and lupus syndrome induced by interferon-β therapy in a patient with multiple sclerosis

Branka Bonači‐Nikolić, Ivica Jeremić, Sladjana Andrejević et al. · Lupus · 2008 · 34 citations